Aniracetam

Fat-soluble racetam

Aniracetam (Fat-soluble racetam) is a cognitive & mood research compound. AMPA-receptor modulator that also influences acetylcholine — mood-leaning focus, faster-acting than piracetam.

How Aniracetam works

AMPA-receptor modulator that also influences acetylcholine — mood-leaning focus, faster-acting than piracetam.

Proposed benefits

Researched for focus, memory, neuroprotection, mood and stress resilience.

Where to get Aniracetam

The evidence for Aniracetam

Graded by what exists behind each claim.

✅ Clinically validated

• Human trials exist from European clinical use — it was studied in Alzheimer's disease and cognitive impairment, with some trials reporting modest benefit. It is prescription medicine in parts of Europe and has never been approved in the US.
• The trial base is old, small by modern standards, and predates current methodological expectations.

📊 Correlative data

• Long community use. Reported experience is distinctive within the family — anxiolytic and 'holistic' rather than stimulating, which is the reason people choose it over the others.

🧪 Theoretical / extrapolated

• An AMPA receptor positive allosteric modulator — it slows receptor desensitization, potentiating glutamatergic signaling implicated in learning. It also affects dopamine and serotonin release in rodent work.
• Fat-soluble and rapidly metabolized, with a half-life under an hour — which predicts the short subjective duration and the argument for taking it with food.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Aniracetam actually does

Aniracetam has two mechanisms, and they belong to two different molecules. That sentence is the whole compound, and no vendor page says it.

Mechanism one, and it belongs to the parent. In Xenopus oocytes expressing rat brain mRNA and in rat hippocampal slices, aniracetam reversibly potentiated quisqualate responses — the 1990 name for the AMPA receptor — while leaving kainate, NMDA and GABA responses untouched Ito 1990. The critical detail is how: potentiation came from an increase in conductance, without any change in receptor affinity or ion selectivity. It is not helping glutamate bind. It is stopping the channel closing on schedule — slowing the desensitization and deactivation that normally shut an AMPA receptor within milliseconds of glutamate arriving. That is why the drug does nothing on its own and shows up only where transmission is already happening: in the slices it enhanced excitatory postsynaptic potentials at Schaffer collateral-commissural–CA1 synapses, not the resting membrane.

And here is the number that should be on every aniracetam page and is on none of them. The potentiation appeared above 0.1 mM Ito 1990. That is 100 micromolar of a 219.24 Da molecule — run the multiplication and it is about 22 micrograms per milliliter of bath fluid. Receptor drugs usually work at nanomolar. This one needs a concentration three orders of magnitude higher, of a parent compound that, as the next section shows, barely reaches plasma at all after a tablet. The AMPA mechanism is real and it was measured in a bath, not in a person.

Mechanism two, and it belongs to the metabolites. In stroke-prone spontaneously hypertensive rats — animals whose cholinergic activity was already lower than controls' — repeated aniracetam raised enzyme activity in the thalamus, and the two metabolites N-anisoyl-GABA and p-anisic acid significantly raised acetylcholine release when applied locally. Injecting N-anisoyl-GABA directly into the tegmental nucleus enhanced release in the reticularis thalami, and the authors conclude that aniracetam enhances cholinergic transmission primarily through its metabolites, with N-anisoyl-GABA the likely contributor to the clinical effect Nakamura 1999.

So the cholinergic effect is downstream of a molecule you did not swallow, acting on a brainstem-to-thalamus pathway, and the glutamate effect is upstream of a concentration you probably never reach. Neither half of that is ‘modulates acetylcholine’.

Cell, rodent, human — and where it stops

Cells and slices. Xenopus oocytes injected with rat brain mRNA, and rat hippocampal slices: reversible potentiation of quisqualate and AMPA responses above 0.1 mM, no effect on kainate, NMDA or GABA, conductance up with affinity unchanged Ito 1990.

Rodent, in a damaged brain. Stroke-prone spontaneously hypertensive rats. The paper's own baseline finding is the one to hold on to: these animals had lower cholinergic activity than controls. Repeated aniracetam raised thalamic enzyme activity; local N-anisoyl-GABA and p-anisic acid raised acetylcholine release Nakamura 1999.

Rodent—or rather bird—in an undamaged brain, which is the experiment this whole family needed and almost never gets. Pigeons, 100–200 mg/kg by injection or by mouth, 30–60 minutes before a delayed matching-to-sample task. Aniracetam had no effect on memory performance and none on response latency. The authors state the conclusion in the title and repeat it in the abstract: promise for restoring memory in damaged brains, no efficacy in a neurologically healthy organism Phillips 2019.

Human. The clinical record is European and elderly. In the review that pooled it, 1,500 mg/day was significantly better than placebo at 4 and 6 months in mild-to-moderate cognitive impairment from senile dementia of the Alzheimer type, and beat piracetam 2,400 mg/day on 8 of 18 tests over 6 months; tolerability was good, with no liver enzyme elevation, and the overall adverse-effect incidence was recorded as undetermined Lee 1994.

The obstacle, and for once it exists as a matched pair rather than an argument. Nakamura's animals were hypertensive and cholinergically depleted and the drug did something Nakamura 1999. Phillips's animals were neurologically healthy and it did nothing Phillips 2019. Same class of task, same drug, opposite results, and the variable that changed was the state of the brain, not the dose — Phillips used 100–200 mg/kg, which is not a shy dose. Every human trial then ran in the third damaged population: elderly people with Alzheimer-type dementia Lee 1994. The reader of this page is in the pigeon's condition, not the rat's. That is the specific obstacle, and it is not ‘more research is needed’. The second obstacle is concentration: the AMPA effect needed more than 0.1 mM in a bath Ito 1990 and nobody has ever published a brain concentration of parent aniracetam in any species after an oral dose.

Aniracetam pharmacokinetics — how much of it actually gets in

This is the most important pharmacokinetic fact in the racetam family and almost no page states it: you do not really take aniracetam. You take a precursor of N-anisoyl-GABA.

What degrades it, chemically. Aniracetam is 1-p-anisoyl-2-pyrrolidinone Ito 1990 — an anisoyl group acylated onto the ring nitrogen of a lactam. An N-acyl lactam is not an ordinary amide: with a carbonyl on either side of that nitrogen, the bond is electron-poor and far more susceptible to hydrolysis than the amide in piracetam or pramiracetam. Hydrolysis opens the ring to give N-anisoyl-GABA — 4-p-anisamidobutyric acid — and onward to p-anisic acid. Both are named as aniracetam's major metabolites and both are pharmacologically active in their own right Nakamura 1999.

How completely, and how we know. The strongest available evidence is the shape of the human pharmacokinetic literature itself. The validated LC-MS/MS method for human plasma was developed for the metabolite, described in its own title as aniracetam's main metabolite, and that assay is what was applied to the pharmacokinetic study after a single oral dose of aniracetam dispersible tablets — linear from 0.0485 to 19.4 micrograms per milliliter, 4.5 minutes per sample, extraction recovery 89.1–100.7% Cai 2012. Read that as a finding, not as a method note. When a human pharmacokinetic study of a drug quantifies the metabolite instead of the drug, the parent was not the measurable species. That is an inference from the study's design rather than a number quoted from it, and it is labeled as one here — but it is corroborated from the other direction by the pharmacology, where the cholinergic effect is credited to the metabolites rather than to aniracetam Nakamura 1999.

Which resolves a contradiction on this site's own card. The quick-facts row says a half-life of about 1–2.5 hours with ‘active metabolites’ in brackets; the theoretical tier below it says a half-life under an hour. Both can be true, of two different molecules — the short one is the parent, the longer one is N-anisoyl-GABA — and a card that does not say which is describing a compound whose exposure is entirely made of the thing in the brackets.

The oral barrier, and why ‘take with fat’ may be doing something more interesting than dissolution. The standard reading is the ordinary one: a poorly water-soluble N-aroyl lactam dissolves better with dietary lipid, bile and slowed gastric emptying. The extrapolation worth stating — and it is extrapolation, flagged as such — is that when first-pass conversion is enzymatic and near-complete, the only lever a person has over how much parent reaches the circulation is the rate at which it is presented to gut wall and liver. Food changes rate. So on this compound, unusually, fat may be changing the parent-to-metabolite ratio rather than simply raising total exposure — which would matter, because the two molecules have different mechanisms. Nobody has measured it. Route: oral, in every study on this page. Unlike oxiracetam, which leaves 84% unchanged in urine, essentially none of an aniracetam dose survives as aniracetam.

What would have to be true, and how you would know it was not

Four predictions. Two of them argue against what the compound is sold for, and the third argues against the advice everybody gives with it.

1. Against: Trail Making will not move in a healthy adult. The only test ever run in a neurologically healthy organism was null at 100–200 mg/kg Phillips 2019, and every positive human result came from Alzheimer-type dementia Lee 1994. Protocol: Trail Making Test A and B at baseline and at 6 weeks, same time of day, and count the B-minus-A difference rather than raw B, because raw B improves with familiarity alone. Prediction: no change beyond practice.

2. Against the standard advice: a choline source should NOT fix this compound's headache, and that is a real experiment. The cholinergic action attributed to aniracetam is not choline uptake at the terminal — it is the metabolite N-anisoyl-GABA acting on the reticulothalamic pathway Nakamura 1999, which is a circuit-level effect with no obvious substrate bottleneck. So if the community's choline advice is transplanted from compounds that act at the transporter, it should fail here. Two weeks at a fixed dose without added choline, two weeks at the same dose with 500 mg of alpha-GPC, headache days counted. If choline abolishes it, the metabolite account is incomplete and that is genuinely new information.

3. GGT and the liver panel should not move, and that is a checkable claim rather than a reassurance. The review record states explicitly that 1,500 mg/day was tolerated without liver enzyme elevation Lee 1994. Draw GGT with a standard metabolic panel at baseline and at 12 weeks. A rise would contradict the only quantitative safety statement this compound has, and would be worth more than another anecdote about focus.

4. The duration prediction, which catches most self-reports. Whatever effect exists rides on the metabolite's curve, and that curve is measured in a couple of hours Cai 2012. Prediction: a single dose should be undetectable by 5–6 hours. Somebody describing an 8-hour effect from one 750 mg dose is describing something other than this drug's pharmacokinetics — caffeine, a training block, or expectancy — and the way to check is to move the dose to the evening and see whether the effect moves with it.

What nobody has tested yet

Five experiments. The first is one assay run and would settle the central question about this molecule.

1. Nobody has published parent and metabolite on the same plasma curve. The human method quantifies N-anisoyl-GABA Cai 2012; the parent's own concentration-time curve after an oral dose is not in the accessible literature. One dual-analyte LC-MS/MS run, twelve subjects, one visit, and the first-pass claim on this page stops being an inference and becomes a ratio.

2. Nobody has measured whether fat changes the ratio rather than the total. A conventional food-effect study reports AUC. The study worth running here reports parent-to-metabolite AUC ratio fed against fasted, because the two molecules do different things Ito 1990 Nakamura 1999. Same subjects, same visit structure, a different primary endpoint — and nobody has framed the question that way.

3. Nobody has given N-anisoyl-GABA to a human. If the metabolite carries the clinical effect Nakamura 1999, the obvious drug is the metabolite. It is a stable substituted benzamide acid, straightforward to synthesize, and it would bypass the entire first-pass problem. In more than thirty years since that was proposed, no human study of it appears in the record.

4. Nobody has repeated the healthy-organism null in a mammal. The one clean negative control for this whole compound class is a pigeon study Phillips 2019. The same delayed matching-to-sample design in healthy rats, or an n-back in healthy adults at 1,500 mg/day, has never been reported — which means the single most relevant experiment for the people actually buying it rests on one species with a very different forebrain.

5. Nobody has connected the bath to the brain. The AMPA effect needed above 0.1 mM Ito 1990. No brain concentration of parent aniracetam after an oral dose has been published in any species. Until somebody puts those two numbers side by side, the claim that oral aniracetam is an AMPA modulator in a living person is an extrapolation across an unmeasured gap, and this page will keep saying so.

Aniracetam — its own safety story, not its class's

The class block is written for cholinergics and stimulants. Aniracetam's own risk story starts somewhere else entirely: with the fact that most of what circulates in you is not the compound on the label.

1. The chronic exposure question is a benzoate question. The two named metabolites are N-anisoyl-GABA and p-anisic acid Nakamura 1999 — and p-anisic acid is 4-methoxybenzoic acid, a simple substituted benzoic acid. Substituted benzoic acids are handled by conjugation and renal excretion, which is a well-trodden disposal route rather than an alarming one; that is chemistry-based extrapolation and is flagged as such, because nobody has published chronic metabolite exposure data in a person taking this daily. The point for the reader is the framing: if you take 1,500 mg a day for six months, the thing your body is chronically clearing is a benzoic acid load, not a nootropic.

2. The one quantitative human safety statement, quoted exactly. Trial data showed good tolerability without liver enzyme elevation, and the adverse-effect incidence was reported as undetermined Lee 1994. Both halves matter. The first is a real negative finding on the organ people worry about. The second means that in 1994, with the European trial base complete, nobody could put a number on how often anything happened — and no one has since. ‘Well tolerated’ on a vendor page is that sentence with the second half deleted.

3. It is a prescription medicine in parts of Europe and has never been approved in the United States. That is a regulatory asymmetry rather than a safety finding, and it cuts both ways: a European prescriber's dossier exists, and no FDA review of it does. On anti-doping, the relevant question for a European prescription medicine is not the stimulant sections that catch phenylpiracetam: aniracetam is a sedating-to-neutral compound with no locomotor signal, and no entry of its own on the current List. Lists are revised every January, so confirm against this year's document before an event.

4. The supply problem, specific to a compound bought as loose powder. European and Australian medicines control laboratories documented 34 distinct unauthorized molecules across 159 nootropic samples and intercepted racetam-family compounds as bulk raw material Vanhee 2025. For aniracetam the practical tell is chemical rather than analytical: an N-acyl lactam is the most hydrolysis-prone bond in this family, so a powder stored warm and damp degrades toward its own metabolite on the shelf. Nobody sells a stability datum with it, and a tub that has partly hydrolyzed is not a fake — it is a different mixture of the same two molecules than the one you dosed last month.

Sources read for this page

• Ito I, Tanabe S, Kohda A, Sugiyama H. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. Journal of Physiology 1990;424:533-543 · PMID 1975272
• Nakamura K, Shirane M. Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam. European Journal of Pharmacology 1999;380(2-3):81-89 · PMID 10513566
• Cai S, Wang L. Determination of aniracetam's main metabolite, N-anisoyl-GABA, in human plasma by LC-MS/MS and its application to a pharmacokinetic study. Journal of Chromatography B 2012;897:50-54 · PMID 22552003
• Phillips H, McDowell A, Mielby BS, Tucker IG, Colombo M. Aniracetam does not improve working memory in neurologically healthy pigeons. PLoS One 2019;14(4):e0215612 · PMID 31002681
• Lee CR, Benfield P. Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs & Aging 1994;4(3):257-273 · PMID 8199398
• Vanhee C, Deconinck E, George M, Hansen A, Hackl A, Wollein U, El-Atma O, Beerbaum N, Aureli F, Borioni A, et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. Journal of Xenobiotics 2025;15(3):88 · PMID 40558871

Aniracetam — safety, predicted from mechanism

Aniracetam — interference & stacking

Bloodwork to run alongside Aniracetam

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Aniracetam — frequently asked questions

Aniracetam inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Aniracetam is used for

Aniracetam appears under 1 goal in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page